{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"MagnetisMM-2","nct_id":"NCT04798586","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magnetismm-2-nct04798586. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"BCMA-CD3 bispecific antibody","label":"Elranatamab (PF-06863135)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-05-17","type":"ACTUAL"},"conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":{"count":4,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Elranatamab (PF-06863135)","otherNames":[],"type":"DRUG"}],"last_update":"2024-09-27","lead_sponsor":"Pfizer","official_title":"A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-05-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 4 weeks"}],"references":[{"citation":"Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T. Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2026 Aug;65(8):1173-1192. doi: 10.1007/s40262-026-01663-z. Epub 2026 Jun 13.","pmid":"42287565","type":"DERIVED"},{"citation":"Lon HK, Hibma J, Jiang S, Sullivan S, Vandendries E, Skoura A, Wang D, Elmeliegy M. Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma. Target Oncol. 2025 Sep;20(5):803-819. doi: 10.1007/s11523-025-01168-y. Epub 2025 Aug 18.","pmid":"40826257","type":"DERIVED"},{"citation":"Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, Hibma J, Lon HK, Piscitelli J, Soltantabar P, Skoura A, Jiang S, Wang D. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Target Oncol. 2025 Mar;20(2):349-359. doi: 10.1007/s11523-025-01134-8. Epub 2025 Feb 25.","pmid":"40000533","type":"DERIVED"},{"citation":"Iida S, Ito S, Yokoyama H, Ishida T, Nagai Y, Handa H, Ito S, Kamei Y, Nakamura M, Suzuki K. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3. Jpn J Clin Oncol. 2024 Sep 4;54(9):991-1000. doi: 10.1093/jjco/hyae068.","pmid":"38794892","type":"DERIVED"}],"start_date":{"date":"2021-03-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04798586"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magnetismm-2-nct04798586"}